Bioventus (BVS) Total Current Liabilities (2020 - 2026)

Bioventus (BVS) has reported Total Current Liabilities for 7 consecutive years, with $152.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities fell 17.9% year-over-year to $152.5 million; the trailing twelve-month figure through Jun 2026 stood at $152.5 million (down 17.9% YoY), and the FY2025 full-year result was $160.4 million, down 23.77% from the prior year.
• Total Current Liabilities rose to $152.5 million in Q2 2026 per BVS's latest filing, from $148.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $304.0 million in Q4 2022 and bottomed at $148.1 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $193.6 million across 5 years, with a median of $177.3 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities surged 79.44% in 2022, then plunged 44.22% in 2023.
• Over 5 years, Total Current Liabilities stood at $304.0 million in 2022, then slumped by 42.27% to $175.5 million in 2023, then increased by 19.89% to $210.4 million in 2024, then retreated by 23.77% to $160.4 million in 2025, then fell by 4.94% to $152.5 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $152.5 million, $148.1 million, and $160.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.